Provided by Tiger Trade Technology Pte. Ltd.

Shattuck Labs, Inc.

6.84
+0.02000.29%
Pre-market: 6.890.0500+0.73%08:17 EDT
Volume:2.02M
Turnover:14.25M
Market Cap:686.48M
PE:-13.65
High:7.29
Open:6.95
Low:6.67
Close:6.82
52wk High:8.33
52wk Low:1.70
Shares:100.36M
Float Shares:67.76M
Volume Ratio:1.33
T/O Rate:2.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5010
EPS(LYR):-0.7014
ROE:-39.21%
ROA:-24.43%
PB:3.25
PE(LYR):-9.75

Loading ...

Shattuck Labs reports Phase 1 data for SL-325 DR3 antibody, with 3.7% antidrug antibody rate

Reuters
·
Jun 10

Shattuck Labs announces common stock offering, no amount given

TIPRANKS
·
Jun 10

Shattuck Labs, Inc. Announces Proposed Public Offering

THOMSON REUTERS
·
Jun 10

Shattuck Labs Is Maintained at Buy by Citigroup

Dow Jones
·
Jun 09

Shattuck Labs receives notices to exercise 50,586,483 common stock warrants, raising USD 54.9 million

Reuters
·
Jun 09

Shattuck Labs - Warrant Exercise Expected to Generate $54.9 Mln in Gross Proceeds

THOMSON REUTERS
·
Jun 09

Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update

THOMSON REUTERS
·
Jun 09

Shattuck Labs Inc : Citigroup Raises Target Price to $18 From $7

THOMSON REUTERS
·
Jun 09

Why Is Shattuck Labs Stock Trading Lower On Monday?

Benzinga
·
Jun 09

Shattuck Labs price target raised to $17 from $14 at Needham

TIPRANKS
·
Jun 08

H.C. Wainwright Sticks to Its Buy Rating for Shattuck Labs (STTK)

TIPRANKS
·
Jun 08

Shattuck Labs Price Target Maintained With a $18.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 08

BRIEF-Shattuck Labs - Announces Phase 1 Data For Sl-325

Reuters
·
Jun 08

Shattuck Labs - Phase 1 Trial of Sl-846 Expected to Initiate in H1 2027

THOMSON REUTERS
·
Jun 08

Shattuck Labs - Antidrug Antibodies to Sl-325 Detected in 3.7% of Participants

THOMSON REUTERS
·
Jun 08

Shattuck Labs - Sl-325 Well Tolerated With Favorable Safety Profile

THOMSON REUTERS
·
Jun 08

Shattuck Labs - No Evidence of DR3 Agonism Observed

THOMSON REUTERS
·
Jun 08

Shattuck Labs Announces Phase 1 Results for SL-325

GlobeNewswire
·
Jun 08

Stocks to Watch: Shattuck Labs

Dow Jones
·
Jun 06

Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8

GlobeNewswire
·
Jun 06